Release Date: 26-Nov-2021
TIGIT Inhibitor Clinical Trials Intelligence Report Insight:
For Report Sample Contact firstname.lastname@example.org
The introduction of immune checkpoint inhibitors in the market have shown to be effective in wide range of cancer and works by restoring the functionality of tumor specific T-cells to combat cancerous cells. Regulatory bodies have approved several immune checkpoint inhibitors which target PD-1/PD-L1 and CTLA4 immune checkpoints. However, studies have shown that only a subset of patients with these types of treatments show durable response, suggesting further research and development in this field. The advancement in genomic analysis has revealed other targetable immune checkpoint including T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT).
TIGIT (also called WUCAM, Vstm3, VSIG9) is a receptor of the immunoglobulin superfamily, which plays a critical role in limiting adaptive and innate immunity. The receptor is expressed by activated CD8+ T and CD4+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and follicular T helper cells in humans. In cancer, the receptor TIGIT has shown to be coexpressed with PD-1 on tumor antigen-specific CD8+ T cells and CD8+ tumor-infiltrating lymphocytes (TILs). Apart from this, several studies have also demonstrated that the expression of TIGIT on TIL of melanoma or gastric cancer patients is associated with metastasis and poor survival rates. Therefore, researchers believed targeting TGIT as an alternative approach for the management of cancer.
The immunomodulatory effects of TIGIT have attracted the attention from pharmaceutical companies worldwide. At present, there are around 15 anti-TIGIT antibodies which are present in preclinical and clinical development for the wide range of cancers. As per our analysis, Roche remains at front foot in the development of anti-TIGIT antibodies. The company has developed tiragolumab, a novel anti-TIGIT immunotherapy which was granted breakthrough therapy designation (BTD) by the FDA for use in combination with atezolizumab (Tecentriq) in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients. Apart from this, Beigene also developed Ociperlimab (BGB-A1217) which is being evaluated in phase-III across wide range of solid tumors. Several major key players including Roche, Gilead Science, Beigene, Acrus Bioscience, Merck, Inovent Biologics and others have developed a robust pipeline of TIGIT inhibitors.
The recent years have seen huge investments in this field which will further propel the growth of market. For instance, GlaxoSmithKline has agreed to buy an anti-TIGIT antibody for cancer immunotherapy from iTeos Therapeutics for US$ 625 Million upfront and up to USs$ 1.45 Billion in milestone payments. In 2020, Gilead Sciences invested US$ 375 Million in Arcus Biosciences and got an option to acquire Arcus's anti-TIGIT antibody AB154 for US$ 275 Million. Gilead could also make US$ 1.23 Billion in future payments. The rising investments in this sector will drive the research and development in this sector during forthcoming years.
The coming years will see increasing incidences of cancer which is mainly attributed to rising adoption rates to sedentary lifestyle and increasing geriatric populations. The limitations of conventional cancer therapies and the ability of TIGIT inhibitors to overcome that, will also drive the growth of market for forecasted period. The global TIGIT inhibitor market is currently present at nascent stage. However, it is expected that the coming years will witness high growth rates in the market which can be justified by the large number of ongoing clinical trials. It is expected that novel TIGIT inhibitors will enter the market by 2023 and will show high adoption rates in the global market owing to their specificity and targetability. Keeping in mind high adoption rates of novel therapies, it is expected that US will dominate the market during the forecast period. Other factors including breakthrough designation, presence of key players, and large target population base will also propel the growth of market during the forecast period.